CLYBL

Across TCGA pan-cancer cohorts, CLYBL mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CLYBL’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CLYBL mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CLYBL is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

HNSC, CCRCC, and PDAC are the cancer types where CLYBL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLYBL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	−1.420	<.001	12	view →
CCRCC	Female	II,III,IV	−1.376	<.001	12	view →
PDAC	Female	II,III,IV	−1.249	<.001	9	view →
COAD	All	IV	−0.610	<.001	9	view →
LUAD	All	III,IV	−0.346	<.001	7	view →
LSCC	Male	All	−0.269	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CLYBL–HNSC

Open the HNSC breakdown →